Analysts Set Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Price Target at $11.00

Posted by on Aug 10th, 2026

Shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX – Get Free Report) have been assigned an average rating of “Moderate Buy” from the six brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $11.00.

A number of brokerages have issued reports on EVAX. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Evaxion A/S in a research report on Friday, April 24th. Weiss Ratings raised Evaxion A/S from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 9th.

Check Out Our Latest Analysis on EVAX

Evaxion A/S Stock Performance

Evaxion A/S stock opened at $3.06 on Monday. The company’s 50-day moving average price is $3.23 and its 200-day moving average price is $3.60. Evaxion A/S has a twelve month low of $2.52 and a twelve month high of $12.15. The company has a quick ratio of 5.85, a current ratio of 5.85 and a debt-to-equity ratio of 0.41. The company has a market cap of $25.52 million, a PE ratio of -2.08 and a beta of 0.29.

Evaxion A/S (NASDAQ:EVAX – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.43). On average, equities research analysts forecast that Evaxion A/S will post -0.5 EPS for the current fiscal year.

Institutional Trading of Evaxion A/S

Institutional investors have recently bought and sold shares of the stock. Rathbones Group PLC purchased a new stake in shares of Evaxion A/S during the first quarter valued at $170,000. Renaissance Technologies LLC purchased a new position in Evaxion A/S in the 1st quarter worth about $146,000. Annis Gardner Whiting Capital Advisors LLC purchased a new position in Evaxion A/S in the 1st quarter worth about $112,000. SmartHarvest Portfolios LLC bought a new stake in Evaxion A/S during the 4th quarter valued at about $72,000. Finally, Wesbanco Bank Inc. bought a new stake in Evaxion A/S during the 4th quarter valued at about $48,000. 11.04% of the stock is currently owned by institutional investors.

Evaxion A/S Company Profile

(Get Free Report)

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.

Featured Stories

Analyst Recommendations for Evaxion A/S (NASDAQ:EVAX)

Receive News & Ratings for Evaxion A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion A/S and related companies with MarketBeat.com's FREE daily email newsletter.